<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01222039</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2008-004014-27</org_study_id>
    <nct_id>NCT01222039</nct_id>
  </id_info>
  <brief_title>Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.</brief_title>
  <acronym>CMM/EICH/2008</acronym>
  <official_title>Multicenter Clinical Trial Phase I/II Randomized, Controlled, for the Evaluation of Safety and Feasibility of Therapy With Two Different Doses of Allogenic Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Progreso y Salud, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Progreso y Salud, Spain</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to assess the safety and feasibility of treatment with
      two-dose infusion of allogeneic mesenchymal stem cells from adipose tissue expanded in vitro
      in patients undergoing haematopoietic stem cell transplantation (HSCT, who have developed
      chronic and extensive graft versus host disease (GVHD).

      Mesenchymal stem cells (MSCs) express low levels of HLA class I molecules, and do not
      express class II molecules neither CD40, CD80 and CD86, being unable to induce proliferation
      of allogeneic lymphocytes. In addition, MSCs inhibit lymphocyte proliferation by inhibiting
      cell division and maintaining these cells in a quiescent state. This supports the hypothesis
      that MSCs are universal suppressors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in each group that may potentially reduce corticosteroids at week 7, 20 and 42, started immunosuppressive treatment and percentage of patients at week 56 have been suspended on full immunosuppressive treatment</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival and disease-free survival.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Chronic and Expanded Graft Versus Host Disease</condition>
  <condition>Immune System Diseases</condition>
  <arm_group>
    <arm_group_label>Conventional treatment plus high dose: 3x10e6 cells / Kg.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment plus low dose: 1x10e6 cells / Kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.</description>
    <arm_group_label>Conventional treatment.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.</intervention_name>
    <description>Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6  / Kg.
Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.</description>
    <arm_group_label>Conventional treatment plus low dose: 1x10e6 cells / Kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.</intervention_name>
    <description>Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.
Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.</description>
    <arm_group_label>Conventional treatment plus high dose: 3x10e6 cells / Kg.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who develop chronic extensive GVHD as determined by the National Institute of
        Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD (Biol
        Blood Marrow Transplant 2005; 11: 945-955), and which meet the following criteria:

          1. They have never received therapy for chronic GVHD.

          2. They have de novo or quiescent chronic extended GVHD.

        Exclusion Criteria:

          1. Concomitant severe systemic infection.

          2. Oncologic or hematological condition relapse.

          3. Pregnancy.

          4. Estimated life expectancy less than 1 week.

          5. Patients who do not give their informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Jurado Chacón, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Haematology Department, Hospital Universitario Virgen de las Nieves de Granada. Spain.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ildefonso Espigado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haematology Department, Hospital Universitario Virgen del Rocío de Sevilla, Spain.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Solano Vercet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haematology and Oncology Department. Hospital Clínico Universitario de Valencia, Spain.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastián Garzón López., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Jerez de la Frontera, Cádiz. Spain.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Cardesa</last_name>
    <phone>+34 955 01 90 40</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Jerez de la Frontera.</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz.</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastián Garzón López, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada.</city>
        <zip>18014.</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Jurado, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío de Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ildefonso Espigado, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Solano Vercet, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.juntadeandalucia.es/terapiasavanzadas/</url>
    <description>Andalusian Initiative for Advanced Therapies</description>
  </link>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>November 4, 2010</lastchanged_date>
  <firstreceived_date>October 14, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Juan Jesús Bandera, Managing Director.</name_title>
    <organization>Fundación Progreso y Salud</organization>
  </responsible_party>
  <keyword>Graft versus host disease</keyword>
  <keyword>Mesenchymal stem cell</keyword>
  <keyword>Allogeneic mesenchymal stem cell</keyword>
  <keyword>Adipose tissue</keyword>
  <keyword>Allotransplant</keyword>
  <keyword>Allogenic</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Chronic</keyword>
  <keyword>Expanded</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
</clinical_study>
